Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

GTX Inc (GTXI)

GTX Inc (GTXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

GTX Inc 17 W Pontotoc Ave. Suite 100 MEMPHIS TN 38103 USA

www.gtxinc.com P: 901-523-9700

Description:

GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx's lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.

Key Statistics

Overview:

Market Capitalization, $K 28,862
Shares Outstanding, K 24,052
Annual Sales, $ 0 K
Annual Net Income, $ -38,420 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,800 K
60-Month Beta 2.23
% of Insider Shareholders 40.90%
% of Institutional Shareholders 9.50%
Float, K 14,215
% Float 59.10%

Growth:

1-Year Return -93.76%
3-Year Return -81.25%
5-Year Return -91.18%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 06/04/19
Earnings Per Share ttm -0.82
EPS Growth vs. Prev Qtr -4.35%
EPS Growth vs. Prev Year 61.29%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-7 on 06/10/19

GTXI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -104.19%
Return-on-Assets % -86.42%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.39
Book Value/Share 0.87
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar